Here are a few analogies to describe Eledon Pharmaceuticals:

• A clinical-stage Regeneron, focusing on antibody treatments for ALS and type 1 diabetes.
• A nascent Biogen, developing novel therapies for autoimmune diseases and ALS.

• AT-1501 - A humanized monoclonal antibody targeting CD40 Ligand, currently in Phase 2a clinical trials for ALS and Phase 2 clinical trials for islet cell transplantation in type 1 diabetes.

Eledon Pharmaceuticals, Inc. (ELDN) is a clinical-stage biopharmaceutical company. Its lead product candidate, AT-1501, is currently in Phase 2 clinical trials for various conditions. As a company in the research and development phase, Eledon Pharmaceuticals does not yet have commercialized products on the market. Therefore, it does not have major customers, whether individuals or other companies, purchasing its products at this time.

Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals since September 2020. He co-founded Imbria Pharmaceuticals Inc., where he also served as Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, he was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He also co-founded Eliem Therapeutics, Inc., and served on its Board of Directors. Outside of Eledon, Dr. Gros is the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products. Eledon Pharmaceuticals was founded in 2020 by Dr. Gros and Dr. Steve Perrin, taking tegoprubart from the ALS Therapy Development Institute into a public company and raising approximately $116 million for its development.

Mr. Little has served as Chief Financial Officer of Eledon Pharmaceuticals since March 2021. He possesses over 30 years of financial, operations, business strategy, and leadership experience in global public companies. Before joining Eledon, Mr. Little served as Chief Financial Officer of Sientra Inc., where he was responsible for finance, investor relations, information technology, and manufacturing, and successfully led multiple public financing rounds. Prior to Sientra, he was Chief Operating Officer for Candela Medical (formerly Syneron-Candela), where he led the company’s global supply chain and service organization and contributed to the execution of a growth strategy that resulted in the company's sale. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC’s Medical Aesthetics division, helping to establish it as a global market leader. He also built the commercial finance, commercial operations, and customer operations functions and led the financial assessment and integration of over $3 billion in M&A activities at Allergan. He began his career in public accounting at KPMG.

Dr. Perrin was the Founder and Chief Executive Officer of Anelixis Therapeutics, Inc., prior to joining Eledon Pharmaceuticals. He brings 20 years of drug development experience, having held R&D positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. Dr. Perrin has collaborated with the ALS Therapy Development Institute to develop a significant ALS drug development program, spanning preclinical and clinical stages. He is recognized as the inventor of tegoprubart.

Dr. Katz has served as Chief Medical Officer of Eledon Pharmaceuticals since November 2023. He joined Eledon from eGenesis, where he previously held the position of Chief Medical Officer, leading the clinical development of xenotransplantation programs. Before eGenesis, Dr. Katz was Vice President of Clinical Development, first at Viela Bio and then at Horizon Therapeutics following its acquisition of Viela Bio. During his time at Horizon and Viela Bio, he spearheaded the clinical development of inebilizumab, overseeing its regulatory submission and approval for neuromyelitis optica spectrum disorder. Prior to Viela Bio, he served as Senior Director of Clinical Development at MedImmune Inc. He also held the role of Senior Director of Transplantation with the Medicine Development Group at Pfizer, where he oversaw research programs involving rapamycin and was instrumental in its regulatory submission and FDA approval for lymphangioleiomyomatosis (LAM). Dr. Katz is an experienced transplant surgeon, having led advancements in liver transplantation at various institutions.

Dr. Hovland has served as Chief Regulatory Officer of Eledon Pharmaceuticals since April 2021, where he is responsible for the company's Regulatory, Quality, and Safety functions. He has over 20 years of R&D experience in the pharmaceutical industry, contributing to the global development and registration of multiple pharmaceutical products. Before joining Eledon, Dr. Hovland was Senior Vice President, Global Regulatory Affairs and Quality at Urovant Sciences from April 2018 to April 2021. From 2010 to 2018, he held leadership roles within the Global Regulatory Affairs organization at Allergan. He also worked in Amgen's Global Regulatory Affairs and Safety organization.

Key Risks to Eledon Pharmaceuticals (ELDN)

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Eledon Pharmaceuticals' success is highly dependent on the successful outcome of its ongoing clinical trials and the subsequent regulatory approval of its lead product candidate, AT-1501 (also known as tegoprubart). There is a significant risk that clinical trials may not meet their primary or secondary endpoints, or that the drug may not demonstrate sufficient safety or efficacy to gain approval from regulatory authorities, such as the FDA. For example, the Phase 2 BESTOW trial for tegoprubart in kidney transplant recipients did not meet its primary efficacy endpoint, which directly illustrates this risk. Such failures or delays could significantly hinder the company's ability to generate revenue and bring its treatments to market.
2. Need for Additional Funding and Profitability Concerns: Eledon Pharmaceuticals has a history of operating losses and a substantial "cash burn" due to the high costs associated with research and development and clinical trials. The company will require significant additional financing to continue its operations, advance its drug candidates, and fund planned clinical trials. There is a risk that Eledon may not be able to secure this additional funding on acceptable terms or at all, which could force the company to significantly alter its business strategy or even lead to liquidation.
3. Dependence on a Single Product Candidate: Eledon Pharmaceuticals' future prospects are heavily reliant on the successful development and commercialization of its lead product candidate, AT-1501 (tegoprubart), for various indications, including ALS, islet cell transplantation, and organ transplantation. While the company has multiple indications for AT-1501 in clinical trials, the overarching dependence on this single asset means that any significant setback or failure related to AT-1501 would have a severe and potentially catastrophic impact on the company's financial condition and viability.

For Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical-stage biopharmaceutical company, the expected drivers of future revenue growth over the next 2-3 years are primarily tied to the advancement and potential commercialization of its lead product candidate, tegoprubart (formerly AT-1501), and related strategic activities.

1. Successful Advancement of Tegoprubart in Kidney Transplantation: Eledon Pharmaceuticals has made significant progress with tegoprubart in kidney transplantation. The company completed enrollment in its Phase 2 BESTOW trial, with topline results anticipated in the fourth quarter of 2025. Positive results from this trial are expected to pave the way for discussions with regulatory authorities, including the FDA, regarding Phase 3 trial design, with plans to initiate Phase 3 development by the end of 2026. The successful progression through late-stage clinical trials is a critical precursor to market approval and eventual revenue generation from drug sales in this significant market. Analysts have indicated a bullish outlook on tegoprubart's potential to improve graft survival and kidney function, positioning it as a potential "best-in-class" immunosuppression therapy.

2. Development and Potential Commercialization of Tegoprubart for Islet Cell Transplantation in Type 1 Diabetes: Eledon has reported positive initial data from subjects with type 1 diabetes treated with tegoprubart following islet transplantation in an investigator-initiated trial, with some patients achieving insulin independence. The company is focused on expanding tegoprubart's potential in this area. Continued positive clinical data and advancement through regulatory pathways for this indication would open another significant therapeutic market for future revenue.

3. Strategic Partnerships and Licensing Agreements: As a clinical-stage company, Eledon Pharmaceuticals' significant progress in its clinical programs, particularly with tegoprubart, can attract strategic partnerships or licensing agreements. Such collaborations could provide upfront payments, milestone payments, and future royalties, thereby generating revenue before direct product sales commence. The company has explicitly stated it is "actively exploring strategic partnerships for islet cell technologies."

4. Expansion into Xenotransplantation: Tegoprubart has been used as a key component of immunosuppression in pioneering pig-to-human xenotransplant procedures, including kidney and heart transplants. While xenotransplantation is an emerging field, Eledon's involvement in these groundbreaking procedures highlights a potential future market for tegoprubart. Early engagement in this innovative area could lead to future revenue streams through collaborations or specialized market entry as the field develops.

Share Issuance

• Eledon Pharmaceuticals announced up to $185 million in gross proceeds from a private placement on May 1, 2023, which included an initial $35 million in exchange for 15.2 million common shares or pre-funded warrants.
• On October 29, 2024, the company priced an underwritten offering of over 18 million shares of common stock and pre-funded warrants, aiming to raise approximately $85 million.
• Eledon Pharmaceuticals completed a $57.5 million underwritten public offering on January 8, 2026, expected to fund operations into the second quarter of 2027.

Inbound Investments

• A private placement announced on May 1, 2023, providing up to $185 million, was led by BVF Partners LP and Armistice Capital, with participation from Sanofi (via Sanofi Ventures).
• On May 7, 2024, Eledon Pharmaceuticals secured approximately $50 million in gross proceeds through an oversubscribed private investment in public equity (PIPE) financing, led by BVF Partners LP.
• The $85 million offering on October 29, 2024, included participation from a group of investors such as BVF Partners LP, RA Capital Management, Frazier Life Sciences, Blue Owl Healthcare Opportunities, First Light Asset Management, Sphera Healthcare, Woodline Partners LP, Nantahala Capital, and T1D Fund.